P. Bürgisser

Discipline

Anthropologie biologique (2) Gestion et management (1)

Type de document

Articles (21) Colloques et conférences (1)

Co-auteur

Date

Source

Mot-clé

Patients (18) Patients (18) virus (14) Treatment (14) Human beings (13) Methods (12) Methods (12) thérapie (11) Therapeutics (11) infection (10) Immunodeficiency (10) Infection (10) cohorte (9) résistance (9) Swiss (8) RNA (8) Drug resistance (7) Transmission (7) Models (7) temps (durée) (6) mutation (6) analyse (6) Time (6) Population (6) Examinations (6) Blood (6) Use (6) Analysis (6) Population (6) Mutation (6)

Documents écrit par P. Bürgisser (22) | parle de P. Bürgisser (0)

An analysis of the benefit of using HEV genotype 3 antigens in detecting anti-HEV IgG in a European population.
A. Schnegg et al. (2013)
Performance evaluation of a new fourth-generation HIV combination antigen-antibody assay.
A. Mühlbacher et al. (2013)
A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C.
C.M. Lange et al. (2012)
A comparison of three anti-HEV IgG EIA screening kits and one confirmatory immunodot assay in blood donor samples in Switzerland
A. Schnegg et al. (2012)
Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection.
R.D. Kouyos et al. (2011)
Hepatitis E Virus Seroprevalence among Blood Donors in Southwest Switzerland.
A. Kaufmann et al. (2011)
The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland.
V. von Wyl et al. (2011)
Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.
J. Fehr et al. (2011)
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.
A.U. Scherrer et al. (2011)
Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.
A.U. Scherrer et al. (2011)
Hepatitis E Virus seroprevalence and chronic infections in patients with HIV, Switzerland.
P. Bürgisser et al. (2011)
High specificity of line-immunoassay based algorithms for recent HIV-1 infection independent of viral subtype and stage of disease.
J. Schüpbach et al. (2011)
Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase
V. von Wyl et al. (2010)
Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load.
S. Alizon et al. (2010)
HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy.
V. von Wyl et al. (2010)
HIV-1 drug resistance transmission networks in southwest Switzerland.
E. Castro et al. (2010)
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
K.J. Metzner et al. (2009)
Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland.
V. von Wyl et al. (2009)
Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.
V. von Wyl et al. (2008)
Assessment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation.
J. Schüpbach et al. (2007)
Nosocomial outbreak of multiple bloodborne viral infections
S. Yerly et al.
Monitoring responses to antiretroviral treatment in human immunodeficiency virus type 1 (HIV-1)-infected patients by serial lymph node aspiration
P. Burgisser et al.